Pharsight

Litfulo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9617258 PFIZER Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
Dec, 2034

(10 years from now)

Litfulo is owned by Pfizer.

Litfulo contains Ritlecitinib Tosylate.

Litfulo has a total of 1 drug patent out of which 0 drug patents have expired.

Litfulo was authorised for market use on 23 June, 2023.

Litfulo is available in capsule;oral dosage forms.

Drug patent challenges can be filed against Litfulo from 24 June, 2027.

The generics of Litfulo are possible to be released after 03 December, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 23, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using RITLECITINIB TOSYLATE ingredient

NCE-1 date: 24 June, 2027

Market Authorisation Date: 23 June, 2023

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

LITFULO family patents

Family Patents